Reduction by dietary matrix metalloproteinase inhibitor BAY 12-9566N of neoplastic development induced by diethylnitrosamine, N-nitrosodimethylamine, or 7,12-dimethylbenz(a)anthracene in rats

Drug and Chemical Toxicology

Volumn 31, Issue 3, 2008, Pages 305-316

  Iatropoulos, Michael J ^a   Cerven, Daniel R ^b   DeGeorge, George ^b   Von Keutz, Eckhard ^c   Williams, Gary M ^a  

^a NEW YORK MEDICAL COLLEGE   (United States)

^b MB Research Laboratories   (United States)

^c BAYER PHARMA AG   (Germany)

Author keywords

Chronic bioassay; Matrix metallopzoteinase inhibitor; Neoplasia reduction; Rat

Indexed keywords

7,12 DIMETHYLBENZ[A]ANTHRACENE; ARYLBUTYRIC ACID DERIVATIVE; BAY 129566N; CARCINOGEN; DIETHYLNITROSAMINE; DIMETHYLNITROSAMINE; MATRIX METALLOPROTEINASE INHIBITOR;

ACCELERATED CANCER BIOASSAY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOASSAY; BREAST ADENOMA; CANCER INHIBITION; CARCINOGENESIS; CARCINOGENICITY; CONTROLLED STUDY; DIET; DRUG INHIBITION; FEMALE; LIVER; LIVER ADENOMA; LUNG; LUNG ADENOMA; MALE; MAMMARY GLAND; NONHUMAN; RAT; STATISTICAL ANALYSIS; WEIGHT GAIN; WISTAR RAT;

9,10-DIMETHYL-1,2-BENZANTHRACENE; ADENOMA; ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOGENS; DIETHYLNITROSAMINE; DIMETHYLNITROSAMINE; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; LIVER NEOPLASMS; LUNG NEOPLASMS; MALE; MAMMARY NEOPLASMS, EXPERIMENTAL; MATRIX METALLOPROTEINASES; NEOPLASMS; ORGANIC CHEMICALS; RATS; RATS, WISTAR; SEX FACTORS;

RATTUS; RATTUS NORVEGICUS;

EID: 47549088106     PISSN: 01480545     EISSN: 15256014     Source Type: Journal    
DOI: 10.1080/01480540701873350     Document Type: Article

References (33)

1. Beckett, R. P., Davidson, A. H., Drummond, A. H., Huxley, P., Whittaker, M. (1996). Recent advances in matrix metalloproteinase inhibitor research. Drug Disc. Ther. 1:16-26.
2. Brown, P. D. (1995). Matrix metalloproteinase inhibitors: a novel class of anticancer agents. Adv. Enzyme Regul. 35:293-301.
3. Egeblad, M., Web, A. (2002). New functions for the matrix metalloproteinases in cancer progression. Nat. Rev. Cancer 2:161-174.
4. Erlichman, C., Adjei, A. A., Alberts, S. R., Sloan, J. A., Goldberg, R. M., Pitot, H. C., Rubin, J., Atherton, P. J., Klee, G. G., Humphrey, R. (2001). Phase I study of the matrix metalloproteinase inhibitor, BAY 12-9566. Ann. Oncol. 12:389-395.
5. Gabriel, K. R. (1978). A simple method of multiple comparisons of means. J. Am. Stat. Assoc. 73:724-729.
6. Genter, M. B., Burman, D. M., Vijayakumar, S., Ebert, C. L., Aronow, B. J. (2002). Genomic analysis of alachlor-induced oncogenesis in rat olfactory mucosa. Physiol. Genom. 12:35-45.
7. Genter, M. B., Warner, B. M., Krell, H. W., Bolon, B. (2005). Reduction of Alachlor-induced olfactory mucosal neoplasms by the matrix metalloproteinase inhibitor RO28-2653. Toxicol. Pathol. 33:593-539.
8. Gomez, D. E., Alonso, D. F., Yoshiji, H., Thorgierrson, U. P. (1997). Tissue inhibitors of metalloproteinases: structure, regulation and biological functions. Eur. J. Cell Biol. 74:111-122.
9. Goss, K. J., Brown, P. D., Matrisian, L. M. (1998). Differing effects of endogenous and synthetic inhibitors of metalloproteinases on intestinal tumorigenesis. Intl. J. Cancer. 78:629-635.
10. Grams, F., Branstetter, H., D'Alo, S., Geppert, D., Krell, H. W., Leinert, H., Livi, V., Menta, E., Oliva, A., Zimmerman, G. (2001). Pyrimidine-2,4-6-triones: a new effective and selective class of matrix metalloproteinase inhibitors. Biol. Chem. 382:1277-1285.
11. Hirte, H., Goel, P., Seymour, L., Huan, S., Stewart, D., Yau, J., Arnold, A., Holohan, S., Waterfield, B., Bates, S., Bennett, K., Walsh, W., Elias, I. (2000). A phase I dose escalation study of the matrix metalloproteinase inhibitor BAY 12-9566 administered orally in patients with advanced solid tumours. Ann. Oncol. 11:1579-1584.
12. Iatropoulos, M. J. (1992). Accelerated rodent bioassy predictive of chemical carcinogenesis. Exp. Toxicol. Pathol. 44:481-487.
13. Iatropoulos, M. J., Williams, G. M., Wang, C. X., Brunnemann, K. D., Leber, A. P. (1997). Assessment of chronic toxicity and carcinogenicity in rats of Wingstay® 100, a rubber antioxidant/antizonant. Exp. Toxicol. Pathol. 49:153-165.
14. Iatropoulos, M. J., Jeffrey, A. M., Enzmann, H. G., von Keutz, E., Schlueter, G., Williams, G. M. (2001). Assessment of chronic toxicity and carcinogenicity in an accelerated cancer bioassy in rats of moxifloxacin, a quinololone antibiotic. Exp. Toxicol. Pathol. 53:345-357.
15. Iatropoulos, M. J., Wang, C. X., von Keutz, E., Williams, G. M. (2006). Assessment of chronic toxicity and carcinogenicity in an accelerated cancer bioassay in rats of Nifurtimox, an antitrypanosomiasis drug. Exp. Toxicol. Pathol. 57:252-259.
16. Levy, D. E., Ezrin, A. M. (1997). Matrix metalloproteinase inhibiting drugs. Emerg. Drugs 2:205-230.
17. Liotta, L., Stetler-Stevenson, W. (1990). Metalloproteinases and cancer invasion. Semin. Cancer Biol. 1:99-106.
18. Lynch, C. C., Matrisian, L. M. (2002) Matrix metalloproteinases in tumor-host communication. Differentiation 70:561-573.
19. Mäkelä, M., Larjava, H., Pirilä, E., Maisi, P., Salo, T., Sorsa, T., Vitto, V-J. (1999). Matrix metalloproteinase 2 (gelatinase A) is related to migration of keratinocytes. Exp. Cell Res. 251:67-78.
20. Maquoi, E., Sounni, N. E., Devy, L, Olivier, F., Frankenne, F., Krell, H. W., Grams, F., Foidart, J. N., Noel, A. (2004). Anti invasive, antitumoral, and antianiogenic efficacy of a pyrimidine-2-4,6-trione derivative, an orally active and selective matrix metalloproteinases inhibitor. Clin. Cancer Res. 10:4038-4047.
21. Ogata, T., Teshima, T., Kagawa, K., Hishikawa, Y., Takahashi, Y., Kawaguchi, A., Suzumoto, Y., Nojima, K., Furusawa, Y., Matsuura, N. (2005). Particle irradiation suppresses metastatic potential of cancer cells. Cancer Res. 65(1):113-120.
22. Peto, R., Pike, M. C., Day, N. E., Gray, R. G., Lee, P. N., Parish, S., Peto, Wahrendorf, J, (1980). Guidelines for simple, sensitive significance tests for carcinogenic effects in long-term animal experiments. In: Montesano, R., Bartsch, H., Tomatis, L., eds. Long-Term and Short-Term Screening Assays for Carcinogens: A Critical Appraisal. IARC Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans, Suppl. 2. Lyon, France: IARC, pp. 311-426.
23. Shepherd, F. A., Giaccone, G., Seymour, L., Debruyne, C., Bezjak, A., Hirsch, V., Smylie, M., Rubin, S., Martins, H., Lamont, A., Krzakowski, J., Sadura, A., Zee, B. (2002). Prospective, randomized, double-blind placebo controlled trial of Marimastat after response to first-line chemotherapy in patients with small-cell lung cancer: A trial of the National Cancer Institute of Canada - Clinical Trials group and the European Organization for Research and Treatment of Cancer. J. Clin. Oncol. 20(22):4434-4439.
24. Stamenkovic, I. (2002). Matrix metalloproteinase in tumor invasion and metastasis. Semin. Cancer Biol. 10:415-433.
25. Stamenkovic, I. (2003). Extracellular matrix remodeling: the role of matrix metalloproteinases. J. Pathol. 200:448-464.
26. Sternlicht, J. D., Werb, Z. (1999). Matrix metalloproteinases. In: Kreis, T., Vale, R., eds. Guidebook to the Extracellular Matrix, Anchor and Adhesion Proteins. New York: Oxford University Press, pp. 503-603.
27. Sternlicht, M. D., Werb, Z. (2001). How matrix metalloproteinases regulate cell behavior. Ann. Rev. Cell Dev. Biol. 17:463-516.
28. Stetler-Stevenson, W. G., Yu, A. E. (2001). Proteases in invasion: matrix metalloproteinases. Semin. Cancer Biol. 11:143-152.
29. Williams, G. M., Iatropoulos, M. J. (2001). Principles of testing for carcinogenic activity. In: Hayes, W., ed. Principles and Methods of Toxicology. Philadelphia, Pennsylvania, USA: pp. 959-1000.
30. Williams, G. M., Iatropoulos, M. J., Weisburger, J. H. (1996). Chemical carcinogen mechanisms of action and implications for testing methodology. Exp. Toxicol. Pathol. 48:101-111.
31. Wyatt, C. A., Geoghegan, J. C., Brinckerhoff, C. E. (2005). Short hairpin RNA-mediated inhibition of matrix metalloproteinase-1 in MDA-231 Cells: effects on matrix destruction and tumor growth. Cancer Res. 65(23):11101-11108.
32. Xu, X., Wang, Y., Chen, Z., Sternlicht, J. D., Hidalgo, M., Steffensen, B. (2005). Matrix metalloproteinase-2 contributes to cancer cell migration on collagen. Cancer Res. 65(1):130-137.
33. Zhou, Y., Yu, C., Miao, X., Tan, W., Liang, G., Xiong, P., Sun, T., Lix, D. (2004). Substantial reduction in risk of breast cancer associated with genetic polymorphisms in the promoters of the matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 genes. Carcinogenesis 25(3):399-404.